Daniel G. S.  Salvadori net worth and biography

Daniel Salvadori Biography and Net Worth

Daniel Salvadori is Abbott's Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products. He was appointed to this role in December 2021.

Previously, Daniel served as Abbott's Executive Vice President, Nutritional Products, and as Senior Vice President, Established Pharmaceuticals, Latin America.

Prior to joining Abbott, Daniel was Chief Executive Officer, LATAM for CFR Pharmaceuticals.

Daniel earned his master's degree in business administration from the Harvard Business School, Boston, Massachusetts.  He is fluent in English, Spanish, French and Italian.

What is Daniel G. S. Salvadori's net worth?

The estimated net worth of Daniel G. S. Salvadori is at least $14.80 million as of March 1st, 2024. Mr. Salvadori owns 125,697 shares of Abbott Laboratories stock worth more than $14,802,079 as of November 22nd. This net worth evaluation does not reflect any other investments that Mr. Salvadori may own. Additionally, Mr. Salvadori receives a salary of $1,760,000.00 as EVP at Abbott Laboratories. Learn More about Daniel G. S. Salvadori's net worth.

How old is Daniel G. S. Salvadori?

Mr. Salvadori is currently 45 years old. There are 6 older executives and no younger executives at Abbott Laboratories. The oldest executive at Abbott Laboratories is Mr. Hubert L. Allen, Executive Vice President, General Counsel and Secretary, who is 58 years old. Learn More on Daniel G. S. Salvadori's age.

What is Daniel G. S. Salvadori's salary?

As the EVP of Abbott Laboratories, Mr. Salvadori earns $1,760,000.00 per year. There are 2 executives that earn more than Mr. Salvadori. The highest earning executive at Abbott Laboratories is Mr. Robert B. Ford, Chairman of the Board, President & CEO, who commands a salary of $4,730,000.00 per year. Learn More on Daniel G. S. Salvadori's salary.

How do I contact Daniel G. S. Salvadori?

The corporate mailing address for Mr. Salvadori and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on Daniel G. S. Salvadori's contact information.

Has Daniel G. S. Salvadori been buying or selling shares of Abbott Laboratories?

Daniel G. S. Salvadori has not been actively trading shares of Abbott Laboratories during the last ninety days. Most recently, Daniel Gesua Sive Salvadori sold 963 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a transaction totalling $114,115.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company's stock, valued at $14,895,094.50. Learn More on Daniel G. S. Salvadori's trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Executive Vice President, General Counsel and Secretary), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Robert Funck, Jr. (EVP), Robert Funck, Jr. (EVP), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), John Mccoy Jr. (VP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 9 times. They sold a total of 246,090 shares worth more than $28,051,118.59. The most recent insider tranaction occured on September, 12th when CEO Robert B Ford sold 141,679 shares worth more than $16,492,852.39. Insiders at Abbott Laboratories own 1.1% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 9/12/2024.

Daniel G. S. Salvadori Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Sell963$118.50$114,115.50125,697View SEC Filing Icon  
8/27/2020Sell42,479$111.86$4,751,700.94144,912View SEC Filing Icon  
6/26/2019Sell71,000$84.00$5,964,000.00167,148View SEC Filing Icon  
6/13/2019Sell10,600$82.00$869,200.0099,479View SEC Filing Icon  
6/11/2019Sell7,269$82.00$596,058.0099,479View SEC Filing Icon  
3/1/2019Sell1,664$78.00$129,792.00108,412View SEC Filing Icon  
9/28/2018Sell5,000$73.39$366,950.0093,321View SEC Filing Icon  
5/18/2018Sell3,000$61.20$183,600.0095,581View SEC Filing Icon  
12/14/2017Sell28,319$54.92$1,555,279.48102,117View SEC Filing Icon  
11/14/2017Sell71,157$55.00$3,913,635.00144,955View SEC Filing Icon  
10/23/2017Sell96,603$56.21$5,430,054.63142,082View SEC Filing Icon  
9/26/2017Sell62,460$52.95$3,307,257.00113,426View SEC Filing Icon  
9/26/2016Sell815$41.71$33,993.6559,791View SEC Filing Icon  
See Full Table

Daniel G. S. Salvadori Buying and Selling Activity at Abbott Laboratories

This chart shows Daniel Gesua Sive Salvadori's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $117.76
Low: $116.38
High: $118.00

50 Day Range

MA: $115.58
Low: $112.23
High: $119.39

2 Week Range

Now: $117.76
Low: $99.71
High: $121.64

Volume

5,247,005 shs

Average Volume

5,695,718 shs

Market Capitalization

$204.25 billion

P/E Ratio

35.79

Dividend Yield

1.88%

Beta

0.72